As of February 27, the U.S. Food and Drug Administration has authorized the use of the Johnson & Johnson vaccine for Americans aged 18 and over.
Although the Biden administration's plan to vaccinate 300 million Americans this year didn't take that approval for granted, the addition of these vaccines to national supplies will likely ease the burden in making that benchmark possible.
According to the Smithsonian Magazine, this vaccine differs from the ones developed by Moderna and Pfizer-BioNTech in that it only requires one shot and doesn't need as strenuous cold storage practices to be functional.
Yet it seems that the U.S. Conference of Catholic Bishops has noticed another difference between the Johnson & Johnson vaccine and the other approved candidates and it's sparked some degree of objection to its ingredients.